


Client Code: LIGAND.217DD

**RECORDATION FORM COVER SHEET  
PATENTS ONLY**

To the Director, U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof.

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>1. Name of conveying party(ies): (List using letters or numbers for multiple parties)</p> <p>Selexis SA</p> <p>Additional name(s) of conveying party(ies) attached?</p> <p>( ) Yes (X) No</p>                                                                                                                                                                                                                                                                                                                              | <p>2. Name and address of receiving party(ies):</p> <p><b>Name:</b> Ligand Pharmaceuticals Incorporated</p> <p><b>Street Address:</b></p> <p>11119 North Torrey Pines Road, Suite 200</p> <p><b>City:</b> La Jolla <b>State:</b> California</p> <p><b>ZIP:</b> 92037</p> <p>Additional name(s) of receiving party(ies) attached?</p> <p>( ) Yes (X) No</p> |
| <p>3. Nature of conveyance:</p> <p>( ) Assignment ( ) Security Agreement</p> <p>( ) Merger ( ) Change of Name</p> <p>(X) Other: <b>Security Interest</b></p> <p>Execution Date: (List as in section 1 if multiple signatures)</p> <p>April 29, 2013</p>                                                                                                                                                                                                                                                                       | <p>4. US or PCT Application number(s) or US Patent number(s):</p> <p>(X) U.S. Patent No.: 7129062; Issued 10/31/2006</p> <p>(X) U.S. Patent No.: 8252917; Issued 08/28/2012</p> <p>(X) U.S. App. No.: 13/536383; Filed 06/28/2012</p> <p>Additional numbers attached?</p> <p>( ) Yes (X) No</p>                                                            |
| <p>5. Party to whom correspondence concerning document should be mailed:</p> <p><b>Customer No.</b> 20,995</p> <p><b>Address:</b> Knobbe, Martens, Olson &amp; Bear, LLP</p> <p>2040 Main Street, 14<sup>th</sup> Floor</p> <p>Irvine, CA 92614</p> <p><b>Return Fax:</b> (949) 760-9502</p> <p><b>Attorney's Docket No.:</b> LIGAND.217DD</p>                                                                                                                                                                                | <p>6. Total number of applications and patents involved: 3</p>                                                                                                                                                                                                                                                                                             |
| <p>7. Total fee (37 CFR 1.21(h)): \$120</p> <p>(X) Authorized to be charged to deposit account</p>                                                                                                                                                                                                                                                                                                                                                                                                                            | <p>8. Deposit account number: 11-1410</p> <p>Please charge this account for any additional fees which may be required, or credit any overpayment to this account.</p>                                                                                                                                                                                      |
| <p>9. Statement and signature.</p> <p>To the best of my knowledge and belief, the foregoing information is true and correct, and any attached copy is a true copy of the original document.</p> <p><u>Joseph M. Reisman</u><br/>Name of Person Signing</p> <p><br/>Signature</p> <p><u>JUNE 03, 2013</u><br/>Date</p> <p>Registration No.<br/>43,878</p> <p>Total number of pages including cover sheet, attachments and document: 11</p> |                                                                                                                                                                                                                                                                                                                                                            |

Documents transmitted via Facsimile to be recorded with required cover sheet information to:

**Mail Stop Assignment Recordation Services**  
 Director, U.S. Patent and Trademark Office  
 P.O. Box 1450  
 Alexandria, VA 22313-1450  
**Facsimile Number: (571) 273-0140**

15359347

700505970

**PATENT**  
**REEL: 030603 FRAME: 0285**

CH \$120.00 111410 1353638

### **PATENT SECURITY AGREEMENT**

This **PATENT SECURITY AGREEMENT** (this "**Patent Security Agreement**") is made this 29<sup>th</sup> day of April, 2013, between **Selexis SA**, a Swiss corporation with offices at 18 chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland ("**Grantor**"), and **Ligand Pharmaceuticals Incorporated**, a Delaware corporation with offices at 11119 North Torrey Pines Road, Suite 200, La Jolla, California 92037, USA ("**Secured Party**").

### **WITNESSETH:**

**WHEREAS**, Secured Party has agreed to provide valuable consideration to Grantor pursuant to a certain Royalty Stream and Milestone Payments Purchase Agreement dated April 29, 2013 (as amended, restated, supplemented or otherwise modified from time to time, the "**Agreement**") between Grantor and Secured Party but only upon the condition, among others, that the Grantor grants a certain security interest in certain collateral to Secured Party; and

**WHEREAS**, pursuant to the Agreement, Grantor is required to execute and deliver to Secured Party this Patent Security Agreement;

**NOW, THEREFORE**, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantor hereby agrees as follows:

**Defined Term.** The defined term "**Patents**" shall mean the patents and patent applications set forth on Schedule I hereto, and all reissues, divisionals, reexaminations, renewals, extensions, provisionals, supplementary protection certificates, continuations and continuations-in-part thereof, and equivalent or similar registered rights anywhere in the world.

**Grant of security interest in patents.** Grantor hereby grants to Secured Party a continuing (as of the date first written above) first security interest in the Patents.

**Security for obligations.** This Patent Security Agreement and the security interest created hereby secure the payment and performance of all of Grantor's obligations to Secured Party under the Agreement, whether such obligations are now existing or arising hereafter. Secured Party shall however not be authorized to, and Secured Party irrevocably and unconditionally covenants not to, exercise (other than to perfect and maintain the security interest) its security interest rights other than in the event of Grantor's bankruptcy, receivership or assignment for the benefit of creditors. Notwithstanding the above, Secured Party shall be authorized, at any time or times after the date of this Patent Security Agreement, at Secured Party's costs and expenses, to the extent necessary to create, maintain and/or perfect the security interest where the respective Patents were issued and to the extent legally permissible, to have control over the security interest provided above and to register the security interest over the Patents with the respective patent offices; and Grantor shall provide Secured Party, at Secured Party's costs and expenses, with any reasonable assistance in connection therewith (including providing additional manually executed and notarized originals of this Patent Security Agreement).

**Agreement.** Each of Grantor and Secured Party hereby acknowledges and affirms that all the terms and provisions of the Agreement are incorporated by reference herein as if fully set forth

herein. In case of conflict between the terms of the Agreement and the terms of this Patent Security Agreement, the terms of the Agreement shall prevail.

**Counterparts.** This Patent Security Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same instrument. In proving this Patent Security Agreement in any proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures delivered by a party by facsimile transmission or by other electronic means of transmission shall be deemed an original executed counterpart hereof.

**Governing Law.** This Patent Security Agreement and the transactions contemplated hereby shall be governed, interpreted and construed by, under and pursuant to the laws of Switzerland, without regard to conflict of laws principles thereof.

**Arbitration.** Any and all disputes, controversies or claims arising out of or relating to this Patent Security Agreement (including the validity, invalidity, breach or termination hereof) shall be exclusively and finally resolved by binding arbitration in accordance with all of the provisions of Section 12.02 of the Agreement.

**In witness thereof,** Grantor and Secured Party have caused this Patent Security Agreement to be executed and delivered by their respective authorized officers as of the date first set forth above.

SELEXIS SA

By: 

Name: Gior Fisco

Title: CFO

LIGAND PHARMACEUTICALS  
INCORPORATED

By: 

Name: Charles Berkman

Title: VP, GC and Secretary

**SCHEDULE I****Patents**

| App/Pub/Pat No.                            | Title                                                 | Assignee                                                                                                        | Filing Date                                                                                  | Issue Date | Expiration Date                                    | Status                                                                                                                                                     | Exemplary Claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|--------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|------------|----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Family 1</b>                            |                                                       |                                                                                                                 |                                                                                              |            |                                                    |                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 10/059,361<br>(US20030087342)<br>7,129,062 | Matrix attachment regions and methods for use thereof | Selexis SA<br>(with a Research license and option agreement recorded 10/12/2007 to Glenmark Pharmaceuticals SA) | 01/28/2002<br>Claims priority to 60/281,391 filed 04/04/2001 and 60/264,355 filed 01/25/2001 | 10/31/2006 | 08/06/2023<br>01/28/2022 + 555 days of PTA (no TD) | Issued, no children                                                                                                                                        | <b>Issued Claim 1:</b><br>A method for transfecting a eukaryotic cell to incorporate a desired gene or portion thereof into said cell wherein the method comprises co-transfecting the cell with unlinked vectors, said unlinked vectors comprising:<br>a first vector comprising a first promoter and a first heterologous gene encoding the desired gene or portion thereof under the transcriptional control of the first promoter, and on first chromatin element,<br>a second unlinked vector comprising a second chromatin element; and<br>a third vector comprising a third vector comprising a second promoter and a second heterologous gene,<br>wherein the chromatin elements are selected from the group consisting of boundary elements, matrix attachment regions, locus control regions and universal chromatin opening elements.<br><b>EP issued claim 1:</b><br>A method for transforming a eukaryotic cell in vitro or ex vivo to incorporate a desired gene or portion thereof by the technique of co-transfecting with unlinked vectors, the method comprising co-transfecting the cell with:<br>a first vector comprising a first promoter and a first heterologous gene encoding the desired gene or portion thereof under the transcriptional control of the first promoter, and one first chromatin element; and,<br>a second unlinked vector comprising a second chromatin element,<br>wherein the chromatin element prevents the |
| PCT/IB2002/002137<br>WO/2002/074969        | Matrix attachment regions and methods for use thereof |                                                                                                                 | 01/28/2002                                                                                   |            | 01/28/2022                                         | AU (granted),<br>CA (granted)<br>EP (granted) - validated in DE, AT, BE, CH, DK, FR, GB, IE, ES, FI, IT, NL, SE, LT, LV,<br>JP (granted),<br>SG (granted). |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

I-I

DOCSCC1620058v1/101501-0008

| App/Pub/Pat No.                                                       | Title                                                                                                                                            | Assignee   | Filing Date                                                      | Issue Date | Expiration Date                                          | Status                                             | Exemplary Claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------------------------------------------------|------------|----------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Family 2</b>                                                       |                                                                                                                                                  |            |                                                                  |            |                                                          |                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 10595495<br>(2007/178469)<br>8,252,917                                | High efficiency<br>gene transfer<br>and expression<br>in mammalian<br>cells by a<br>multiple<br>transfection<br>procedure of<br>MAR<br>sequences | SELEXIS SA | 04/24/2006<br>NP of<br>PCT/EP2004/011<br>974 filed<br>10/22/2004 | 08/28/2012 | 05/14/2026<br>10/22/2024 +<br>569 days of<br>PTA (no TD) | Issued, child<br>13/536,383<br>filed<br>06/28/2012 | <p><b>Issued Claim 1:</b><br/>A purified and isolated DNA sequence comprising: a) at least one bent DNA element and/or at least 33% of the dinucleotide TA stretch of 100 contiguous base pairs, b) at least one binding site for a DNA binding protein, wherein said purified and isolated DNA sequence is a MAR nucleotide sequence with sequence ID NO: 25, or a sequence complementary to sequence ID NO: 25, or a sequence having at least 90% identity with said SEQ ID NO: 25.</p> <p>37. A purified and isolated DNA sequence, wherein said DNA sequence comprises a) at least one bent DNA element, b) and at least one binding site for a DNA binding protein, and wherein said DNA sequence is a MAR nucleotide with SEQ ID NO: 25, or a sequence complementary thereof, or a sequence having at least 90% identity with said sequence.</p> <p>38. A synthetic MAR sequence comprising natural human MAR elements and/or fragments thereof assembled between linker sequences, wherein the MAR sequence is sequence ID NO: 25, or a sequence complementary to sequence ID NO: 25, or a sequence having at least 90% identity with said SEQ ID NO: 25.</p> |
| 13/536,383                                                            |                                                                                                                                                  |            | 06/28/2012                                                       |            |                                                          | Information not available on PAIR                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Claims priority to '917 patent<br>PCT/EP2004/011974<br>WO/2005/040377 | High efficiency<br>gene transfer<br>and expression                                                                                               |            | 10/22/2004<br>Claims priority to                                 |            | 10/22/2024                                               | Filed in AU,<br>CA, CN, EP<br>(5), HK, IL (2),     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

I-2

DOCNO:1620058v1/101501-0008

| App/Pub/Pat No. | Title                                                                                         | Assignee | Filing Date                                                           | Issue Date | Expiration Date | Status                                                                                                                                            | Exemplary Claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------|-----------------------------------------------------------------------------------------------|----------|-----------------------------------------------------------------------|------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                 | in mammalian cells by a multiple transfection procedure of matrix attachment region sequences |          | 60/513,574 (US) filed 10/24/2003 and 04002722.9 (EP) filed 02/06/2004 |            |                 | IN, JP, KR (5), RU, SG, US, ZA                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| EP1675952       |                                                                                               |          | 03/28/2006<br>NIP of PCT/EP2004/011 974 filed 10/22/2004              |            |                 | Withdrawn                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| EP1959011       |                                                                                               |          | Divisional of EP1675952                                               |            | 10/22/2024      | Granted<br>Validated in:<br>AT, BE, CH<br>CZ, DE, DK,<br>EE, ES, FI,<br>FR, GB, GR,<br>HU, IE, IT, LT,<br>LU, LV, MC,<br>NL, PL, PT SE,<br>SI, TR | Issued Claim 1:<br>A purified and isolated DNA sequence having protein production increasing activity, characterized in that said DNA sequence comprises a) at least one bent DNA element, wherein the bent DNA element contains at least 33% of dinucleotide TA, and/or at least 33% of dinucleotide AT on a stretch of 100 contiguous base pairs, b) at least one binding site for a DNA binding protein, and that it is a MAR nucleotide sequence with the sequence SEQ ID No 25, or a sequence complementary thereof, or a sequence having at least 90% identity with said sequence SEQ ID No 25. |
| EP2287302       |                                                                                               |          | Divisional of EP1675952                                               |            | 10/22/2024      | Intent to Grant issued 07/18/2012                                                                                                                 | Claim 1:<br>A purified and isolated DNA sequence having protein production increasing activity characterized in that said DNA sequence comprising a) at least one bent DNA element, wherein the bent DNA element contains at least 33% of the dinucleotide TA and/or at least 33% of the dinucleotide AT on a stretch of 100 contiguous base pairs, b) at least one binding site for a DNA binding protein, and that it is a MAR nucleotide sequence with the sequence SEQ ID No 24, or a sequence complementary thereof, or a sequence having                                                        |

I-3

DOCSOC1620058v1/101501-0008

| App/Pub/Pat No. | Title | Assignee | Filing Date                                        | Issue Date | Expiration Date | Status                                  | Exemplary Claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------|-------|----------|----------------------------------------------------|------------|-----------------|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| EP2292754       |       |          | Divisional of<br>EP1675952                         |            | 10/22/2024      | Intent to Grant<br>issued<br>07/20/2012 | <p>at least 90% identity with said sequence SEQ ID No 24.</p> <p><b>Claim 1:</b><br/>A purified and isolated DNA sequence having protein production increasing activity characterized in that said DNA sequence comprising a) at least one bent DNA element, wherein the bent DNA element contains at least 33% of the dinucleotide TA and/or at least 33% of the dinucleotide AT on a stretch of 100 contiguous base pairs, b) at least one binding site for a DNA binding protein, and that it is a MAR nucleotide sequence with the sequence SEQ ID No 26, or a sequence complementary thereof, or a sequence having at least 90% identity with said sequence SEQ ID No 26.</p> |
| EP2298898       |       |          | Divisional of<br>EP1675952                         |            | 10/22/2024      | Intent to Grant<br>issued<br>07/20/2012 | <p><b>Claim 1:</b><br/>A purified and isolated DNA sequence having protein production increasing activity characterized in that said DNA sequence comprising a) at least one bent DNA element, wherein the bent DNA element contains at least 33% of the dinucleotide TA and/or at least 33% of the dinucleotide AT on a stretch of 100 contiguous base pairs, b) at least one binding site for a DNA binding protein, and that it is a MAR nucleotide sequence with the sequence SEQ ID No 27, or a sequence complementary thereof, or a sequence having at least 90% identity with said sequence SEQ ID No 27.</p>                                                               |
| AU2004284220    |       |          | NP of<br>PCT/EP2004/011<br>974 filed<br>10/22/2004 |            |                 | Granted<br>09/22/2010                   | <p><b>Issued Claim 1:</b><br/>A purified and isolated DNA sequence having protein production increasing activity comprising:<br/>a) at least one bent DNA element, and<br/>b) at least one binding site for a DNA binding protein,<br/>wherein said DNA sequence is a MAR nucleotide with a sequence selected from the following:</p>                                                                                                                                                                                                                                                                                                                                              |

I-4

DOCSOC/1620058.v1/101501-0008

| App/Pub/Pat No. | Title | Assignee | Filing Date                   | Issue Date | Expiration Date | Status                | Exemplary Claims                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------|-------|----------|-------------------------------|------------|-----------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AU2010236093    |       |          | Divisional of<br>AU2004284220 |            |                 | Granted<br>09/29/2011 | <p>(i) SEQ ID NO:25,<br/>(ii) a sequence complementary to SEQ ID NO:25,<br/>(iii) a sequence at least 70% identical to SEQ ID NO:25.</p> <p><u>Issued Claim 1:</u><br/>A purified and isolated DNA sequence having protein production increasing activity characterized in that said DNA sequence comprises:<br/>a) at least one bent DNA element, wherein the bent DNA element contains at least 33% of the dinucleotide TA and/or at least 33% of the dinucleotide AT on a stretch of 100 contiguous base pairs,<br/>b) at least one binding site for a DNA binding protein,<br/>c) and that it is a MAR nucleotide sequence with the sequence SEQ ID NO:24, or a sequence complementary thereof, or a sequence having at least 90% identity with said sequence.</p> |
| AU2010236091    |       |          | Divisional of<br>AU2004284220 |            |                 | Granted<br>06/17/2011 | <p><u>Issued Claim 1:</u><br/>A purified and isolated DNA sequence having protein production increasing activity comprising:<br/>a) at least one bent DNA element, and<br/>b) at least one binding site for a DNA binding protein,<br/>wherein said DNA sequence is a MAR nucleotide with a sequence selected from the following:<br/>(i) SEQ ID NO:27,<br/>(ii) a sequence complementary to SEQ ID NO:27,<br/>(iii) a sequence at least 90% identical to SEQ ID NO:27.</p>                                                                                                                                                                                                                                                                                            |
| AU2010236072    |       |          | Divisional of<br>AU2004284220 |            |                 | Granted<br>08/11/2011 | <p><u>Issued Claim 1:</u><br/>A purified and isolated DNA sequence having protein production increasing activity characterized in that said DNA sequence comprises:</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

I-5

DOCNO:1620058v1/101501-0008



| App/Pub/Pat No. | Title | Assignee | Filing Date | Issue Date | Expiration Date | Status | Exemplary Claims                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------|-------|----------|-------------|------------|-----------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                 |       |          |             |            |                 |        | a) at least one bent DNA element, wherein the bent DNA element contains at least 33% of the dinucleotide TA and/or at least 33% of the dinucleotide AT on a stretch of 100 contiguous base pairs,<br>b) at least one binding site for a DNA binding protein,<br>c) and that it is a MAR nucleotide sequence with the sequence SEQ ID NO:26, or a sequence complementary thereof, or a sequence having at least 90% identity with said sequence. |

MARtech 2: China 2004284220 granted 31.01.2011  
Russia 019323: granted 05.08.2009  
South Africa 2006/4032: granted 28.05.2008

I-6

DOCSOC/1620058v1/101501-0008

STATE OF CALIFORNIA

COUNTY OF SAN DIEGO

On April 29, 2013, before me, Olivia Holiday,  
Date Name And Title Of Officer (e.g. "Jane Doe, Notary Public")personally appeared Igor Edouard Fisch,  
Name of Signer(s)


who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature: O. Holiday

(Seal)



STATE OF CALIFORNIA

COUNTY OF SAN DIEGO

On April 29, 2013

Date

, before me, Olivia Holiday

Name And Title Of Officer (e.g. "Jane Doe, Notary Public")

personally appeared Charles Berkman

Name of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/~~she/they~~ executed the same in his/~~her/their~~ authorized capacity(ies), and that by his/~~her/their~~ signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature: O. Holiday

(Seal)

